By Tova Cohen and Steven Scheer TEL AVIV (Reuters) - Israeli turnaround specialist Erez Vigodman, the chief executive of Teva Pharmaceutical Industries , is looking to pull off the ultimate transformation, with the biggest deal in Israel's corporate history. His unsolicited $40 billion offer for smaller generic drug rival Mylan Inc is Vigodman's attempt to turn Teva into a global drug powerhouse with a $100 billion market valuation, a far cry from its start as a small wholesale drug business in Jerusalem more than a century ago. Despite having no pharmaceutical experience, Vigodman, 55, was hired by Teva in February last year after he had turned around MA Industries, an Israeli agro-chemicals group. At MA Industries, today called Adama, Vigodman restored profitability and invested in growth areas.
via Health News Headlines - Yahoo News http://ift.tt/1IHvf7S
No comments:
Post a Comment